|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESEARCH PAPER
Department of Molecular Genetics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Loss of OVCA1/DPH2L1 correlates with ovarian and breast cancer. To study its in vivo role, we generated Ovca1 mutant alleles in mice. Ovca1 heterozygotes spontaneously develop cancer. Ovca1 mutant mice die during embryonic development and at birth with developmental delay and defects in multiple organ systems. Cell proliferation defects were observed in Ovca1 mutant mouse embryonic fibroblasts (MEFs). p53 deficiency can rescue these Ovca1 mutant MEF proliferation defects and partially rescue Ovca1 mutant embryonic phenotypes. Furthermore, Ovca1; p53 double heterozygotes developed tumors quicker than p53 heterozygotes and with an increased carcinoma incidence. Multiple tumor burden in Ovca1 heterozygotes that were also p53 deficient was significantly higher than in p53 homozygous mutants. These in vivo findings demonstrate that Ovca1 is a tumor suppressor that can modify p53-induced tumorigenesis and suggest that it acts as a positive regulator for cell cycle progression. The close linkage of OVCA1 and p53 on human Chromosome 17 suggests that coordinated loss may be an important mechanism for the evolution of ovarian, breast, and other tumor phenotypes.
[Keywords: Tumor suppressor; ovarian cancer; DPH2L1; Ovca2; HIC1; Miller-Dieker syndrome]
Received October 17, 2003; revised version accepted December 18, 2003.
Supplemental material is available at http://www.genesdev.org.
1 Present address: Faculty of Life Sciences, National Yang-Ming University, Taipei 112, Taiwan.
2 Corresponding author.
E-MAIL rrb{at}mdanderson.org; FAX (713) 794-4394.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Liu, J. F. Wiggins, T. Sreenath, A. B. Kulkarni, J. M. Ward, and S. H. Leppla Dph3, a Small Protein Required for Diphthamide Biosynthesis, Is Essential in Mouse Development Mol. Cell. Biol., May 15, 2006; 26(10): 3835 - 3841. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. He, B. J. Fenner, A. K. Godwin, and J. Kwang White Spot Syndrome Virus Open Reading Frame 222 Encodes a Viral E3 Ligase and Mediates Degradation of a Host Tumor Suppressor via Ubiquitination. J. Virol., April 1, 2006; 80(8): 3884 - 3892. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nobukuni, K. Kohno, and K. Miyagawa Gene Trap Mutagenesis-based Forward Genetic Approach Reveals That the Tumor Suppressor OVCA1 Is a Component of the Biosynthetic Pathway of Diphthamide on Elongation Factor 2 J. Biol. Chem., March 18, 2005; 280(11): 10572 - 10577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, G. T. Milne, J. G. Kuremsky, G. R. Fink, and S. H. Leppla Identification of the Proteins Required for Biosynthesis of Diphthamide, the Target of Bacterial ADP-Ribosylating Toxins on Translation Elongation Factor 2 Mol. Cell. Biol., November 1, 2004; 24(21): 9487 - 9497. [Abstract] [Full Text] [PDF] |
||||